axicabtagene ciloleucel

AssetAlso called KTE-C19, Yescarta

Engineered CAR T cells recognize CD19 and kill CD19-expressing B cells, including malignant cells.

Stage
Approved
Modality
Cell therapy
Target
CD19
8
Indications
39
Trials
1
Developer

Approved by the FDA on Oct 18, 2017 (BLA125643). 2 approvals stand. FDA

Indications

8
  • Diffuse large B-cell lymphoma

    Approved, FDA

  • DLBCL Arising From Follicular Lymphoma

    Approved, FDA

  • Follicular lymphoma

    Approved, FDA

5 more

In the full profile

  • Target and mechanism1
  • Owner and partners1
  • Trials39
  • Evidence for its targets2
  • Competitors11
  • Signals6

Every asset’s record: target, stage, trials and the evidence behind it.

See Pro

Assets